Grant: Doctoral Research Award - Priority Announcement: Amyotrophic Lateral Sclerosis
University of British Columbia
$39,000.00
Prion-like intermolecular transmission of superoxide dismutase 1 (SOD1) misfolding in embryonic spinal cord cultures of an amyotrophic lateral sclerosis (ALS) mouse model.
EF 2010-11
Résumé
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a common and incurable disorder that affects the nerve cells in the central nervous system (CNS) that control voluntary muscle movement. There is currently no cure for ALS, which afflicts 2,500-3,000 Canadians, and ~30,000 people in North America. The survival after diagnosis is bleak, with 80% of patients dying within 2-5 years. Hereditary forms of ALS can be caused by genetic mutations that alter a cellular defense protein called superoxide dismutase 1 (SOD1). SOD1 normally functions to help protect cells from damage, but when the three-dimensional shape of the protein changes, it can take on an opposite role and contribute to cell death. There is growing evidence that ALS is associated with abnormal changes in the three-dimensional shape of SOD1. Our laboratory has evidence that altered SOD1 can change normal SOD1 to a toxic form that can then go on to change other normal forms of the protein. This "chain reaction" can occur inside cells and can travel from one cell to another. We predict that this process is how ALS spreads throughout the nervous system. I aim to test this disease process in systems that more reflect the nervous system of humans. We will study this mechanism in mouse nerve cell models of ALS, which will allow us to see if diseased SOD1 can be passed from one nerve cell to another, and test molecules that could block the toxic chain-reaction of altered SOD1, thereby stopping the spread of the disease. It is essential that we understand the biological mechanism of this disease so new treatment strategies and/or vaccines can be developed.
Programme
Doctoral Research Award - Priority Announcement: Amyotrophic Lateral Sclerosis
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
218769
Name
O'Neill Megan A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Amyotrophic Lateral Sclerosis Society of Canada
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Prion-like intermolecular transmission of superoxide dismutase 1 (SOD1) misfolding in embryonic spinal cord cultures of an amyotrophic lateral sclerosis (ALS) mouse model.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$39,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - Priority Announcement: Amyotrophic Lateral Sclerosis
Keyworddelim
Als; Immunoprecipitation; Mouse Model; Neurodegeneration; Protein Misfolding; Sod1; Spinal Cord Cultures; Template Directed Misfolding
Abstract
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a common and incurable disorder that affects the nerve cells in the central nervous system (CNS) that control voluntary muscle movement. There is currently no cure for ALS, which afflicts 2,500-3,000 Canadians, and ~30,000 people in North America. The survival after diagnosis is bleak, with 80% of patients dying within 2-5 years. Hereditary forms of ALS can be caused by genetic mutations that alter a cellular defense protein called superoxide dismutase 1 (SOD1). SOD1 normally functions to help protect cells from damage, but when the three-dimensional shape of the protein changes, it can take on an opposite role and contribute to cell death. There is growing evidence that ALS is associated with abnormal changes in the three-dimensional shape of SOD1. Our laboratory has evidence that altered SOD1 can change normal SOD1 to a toxic form that can then go on to change other normal forms of the protein. This "chain reaction" can occur inside cells and can travel from one cell to another. We predict that this process is how ALS spreads throughout the nervous system. I aim to test this disease process in systems that more reflect the nervous system of humans. We will study this mechanism in mouse nerve cell models of ALS, which will allow us to see if diseased SOD1 can be passed from one nerve cell to another, and test molecules that could block the toxic chain-reaction of altered SOD1, thereby stopping the spread of the disease. It is essential that we understand the biological mechanism of this disease so new treatment strategies and/or vaccines can be developed.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
O'Neill, Megan A
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $39,000~ $0~